M. Saleh

发表

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.

J. Posey, A. Lobuglio, M. Khazaeli, 2001, Cancer biotherapy & radiopharmaceuticals.

Abiraterone and increased survival in metastatic prostate cancer.

Arturo Molina, Tina Cheng, Fred Saad, 2011, The New England journal of medicine.

Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.

J. Schlom, R. Meredith, R. Wheeler, 1991, Cancer research.

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

David Goldstein, Manuel Hidalgo, Thomas Ervin, 2013, The New England journal of medicine.

Bridging the Gap in Training and Clinical Practice in Sub-Saharan Africa

G. Naik, S. Sayed, A. Sohani, 2019, Current Breast Cancer Reports.

Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.

J. Schlom, R. Meredith, R. Wheeler, 1997, Cancer biotherapy & radiopharmaceuticals.

Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers.

S. Spencer, R. Meredith, K. P. Raisch, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC).

H. Scher, C. Redfern, E. Antonarakis, 2012 .

Immunologic Response to the Dual Murine Anti‐Id Vaccine Melimmune‐1 and Melimmune‐2 in Patients with High‐Risk Melanoma Without Evidence of Systemic Disease

J. Murray, A. Solinger, A. Lobuglio, 1998, Journal of immunotherapy.

Artificial intelligence and machine learning for early detection and diagnosis of colorectal cancer in sub-Saharan Africa

Geoffrey H. Siwo, S. Saini, G. Kwakye, 2022, Gut.

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide

H. Scher, E. Antonarakis, C. Higano, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects.

R. Wheeler, A. Lobuglio, M. Khazaeli, 1988, Journal of the National Cancer Institute.

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

E. Winer, N. Robert, R. Carlson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

So You Want to Be a Principal Investigator.

G. Naik, M. Saleh, 2018, Journal of oncology practice.

Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.

J. Schlom, R. Meredith, R. Wheeler, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.

D. Govender, S. Sayed, P. Bird, 2014, Breast.

Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).

J. Posey, F. Luo, J. Shah, 2010, Cancer biotherapy & radiopharmaceuticals.

Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting

Lei Chen, K. Sail, M. Saleh, 2014, Current medical research and opinion.

First-In-Human Phase 1 Clinical Trials – A Single-Center Experience In The Era Of Modern Oncotherapeutics

G. Naik, P. Li, R. Paluri, 2020, Scientific Reports.

Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors

P. Li, R. Paluri, M. Saleh, 2019, Cancer Chemotherapy and Pharmacology.

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.

L. Gordon, M. Czuczman, D. Maloney, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).

N. Senzer, J. Bendell, A. Lockhart, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).

M. Socinski, M. Saleh, P. Stella, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of the impact and burden of illness of adult chronic ITP in the US

M. Fisher, M. Saleh, K. Grotzinger, 2009, Current medical research and opinion.

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone

H. Scher, E. Antonarakis, D. Rathkopf, 2017, Clinical Cancer Research.

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.

R. Herbst, F. Fossella, G. Blumenschein, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

L. Gordon, M. Czuczman, D. Klippenstein, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changing Treatment Paradigms for Myelodysplastic Syndromes in a Community Oncology Practice: Georgia Cancer Specialists' Experience

B. Feinberg, M. Saleh, J. Gilmore, 2007 .

Academic Cancer Center Phase I Program Development

J. Berlin, K. Flaherty, E. Frenkel, 2017, The oncologist.

Breast cancer diagnosis in a resource poor environment through a collaborative multidisciplinary approach: the Kenyan experience

C. Kyobutungi, S. Sayed, P. Bird, 2013, Journal of Clinical Pathology.

Demographic, Clinical, and Co-Morbidity Characteristics of COVID-19 Patients: A Retrospective Cohort from a Tertiary Hospital in Kenya

S. Sayed, M. Saleh, Jasmit S. Shah, 2022, International journal of general medicine.

A pilot phase Ib/II study of whole-lung low dose radiation therapy (LDRT) for the treatment of severe COVID-19 pneumonia: First experience from Africa

Stacey M. O. Gondi, S. Sayed, M. Saleh, 2022, PloS one.

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.

J. Murray, N. Onetto, D. Healey, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I T rial o f t he A nti-Lewis Y D rug I mmunoconjugate BR96-Doxorubicin i n P atients W ith L ewis Y -Expressing Epithelial T umors

J. Murray, N. Onetto, Dennie V. Jones, 2000 .

Phase I Trial of an Anti‐CD19 Deglycosylated Ricin A Chain Immunotoxin in Non‐Hodgkin's Lymphoma: Effect of an Intensive Schedule of Administration

E. Vitetta, A. Lobuglio, T. Liu, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response.

R. Wheeler, A. Lobuglio, M. Khazaeli, 1988, Journal of the National Cancer Institute.

A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.

W. Grizzle, J. Posey, M. Bookman, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Promoting Best Practice in Cancer Care in Sub Saharan Africa

S. Sayed, M. Saleh, K. Sharma, 2022, Frontiers in Medicine.

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.

J. Bussel, M. Arning, M. Saleh, 2013, Blood.

Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.

M. Hidalgo, M. Reni, J. Tabernero, 2013 .

BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC->T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.

M. Buyse, G. Sauter, J. Mackey, 2009 .

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

C. Redfern, C. Higano, M. Carducci, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor.

L. Minasian, D. Munn, L. Weiner, 1995, Blood.

Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).

M. Hidalgo, M. Reni, E. Van Cutsem, 2013 .

A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

J. Posey, J. Shah, A. Forero-Torres, 2008 .

Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma.

M. Urist, R. Wheeler, A. Lobuglio, 1988, Journal of Clinical Oncology.

Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.

F. Guadagni, J. Schlom, E. Borden, 1991, Cancer research.

Phase I clinical trial of CO17-1A monoclonal antibody.

R. Wheeler, A. Lobuglio, M. Khazaeli, 1986, Hybridoma.

Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.

C. Flowers, S. Dakhil, P. Mclaughlin, 2006 .

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

D. Lake, C. Hudis, T. Traina, 2010, Clinical breast cancer.

Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.

J. Schlom, A. Lobuglio, R. Arani, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody

A. Lobuglio, M. B. Khazaeli, M. Khazaeli, 1992, Journal of Clinical Immunology.

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.

J. Burke, J. Radich, H. Kantarjian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

J. Hecht, S. Dakhil, W. Go, 2013 .

Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)

J. Bussel, M. Arning, M. Saleh, 2013, British journal of haematology.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

K. Bland, H. Krontiras, C. Falkson, 2010, Clinical breast cancer.

Breast Camps for Awareness and Early Diagnosis of Breast Cancer in Countries With Limited Resources: A Multidisciplinary Model From Kenya.

S. Dawsey, S. Sayed, J. Zujewski, 2016, The oncologist.

Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.

M. Urist, R. Wheeler, A. Lobuglio, 1992, Cancer research.

Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.

W. Grizzle, A. Yu, S. Gillies, 1992, Human antibodies and hybridomas.

Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.

Suzanne F. Jones, J. Bendell, L. Camacho, 2010 .

3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial

W. Scheithauer, H. Lenz, A. Zubel, 2007 .

Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer

L. Saltz, J. Cassidy, J. Fuloria, 2007 .

Therapeutic optimization of aromatase inhibitor–associated arthralgia: etiology, onset, resolution, and symptom management in early breast cancer

B. Feinberg, M. Saleh, S. Simmons, 2012 .

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

M. Buyse, G. Sauter, J. Mackey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

J. Hainsworth, G. Schiller, D. Rizzieri, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.

J. Bussel, R. Wong, A. Khelif, 2017, Blood.

Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study

J. Bussel, M. Aivado, B. Meddeb, 2008 .

Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia

Shaw, A. Lobuglio, M. Saleh, 1987 .

A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data

Jeannette Y Lee, R. Wheeler, A. Lobuglio, 2005, Cancer Immunology, Immunotherapy.

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.

J. Vose, A. Zelenetz, M. Kaminski, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.

J. Schlom, W. Grizzle, R. Meredith, 1993, Cancer research.

Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer

P. Triozzi, J. Rinehart, G. Bolger, 2005, The Prostate.

Phase I study of anti-epidermal growth factor receptor (anti-EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)

S. Spencer, R. Meredith, A. Lobuglio, 1998 .

CD 16 + Monocytes in Patients With Cancer : Spontaneous Elevation and Pharmacologic Induction by Recombinant Human Macrophage Colony-Stimulating Factor

Goldman, L. Minasian, D. Munn, 2000 .

Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice

B. Feinberg, M. Saleh, J. Gilmore, 2009 .

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

J. Vose, A. Zelenetz, M. Kaminski, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.

M. Ross, J. Murray, A. Buzaid, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Immune thrombocytopenia: effects of maternal gamma globulin infusion on maternal and fetal serum, platelet, and monocyte IgG.

J. Barton, A. Lobuglio, M. Saleh, 1987, American Journal of the Medical Sciences.

In vitro effects of gammaglobulin (IgG) on human monocyte Fc receptor function. I. Effect on monocyte membrane‐associated IgG and Fc receptor‐dependent binding of antibody‐coated platelets

A. Lobuglio, M. Saleh, W. Court, 1986, American journal of hematology.

Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy.

W. Grizzle, R. Meredith, A. Lobuglio, 1998, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

A Community‐Oriented Approach to Breast Cancer in a Low‐Resource Setting: Improving Awareness, Early Detection and Treatment of Breast Cancer in Tajikistan

F. Amersi, A. Jiwani, Farin Amersi, 2016, The breast journal.

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

J. Bussel, M. Arning, B. Psaila, 2007, The New England journal of medicine.

Monocyte-platelet interaction in immune and nonimmune thrombocytopenia.

A. Lobuglio, M. Saleh, J. Lee, 1989, Blood.

Quinidine-induced immune thrombocytopenia.

A. Lobuglio, M. Saleh, K. Allen, 1989, Henry Ford Hospital medical journal.

Ethnicity and breast cancer characteristics in Kenya

Gretchen L. Gierach, S. Dawsey, C. Kyobutungi, 2017, Breast Cancer Research and Treatment.

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

J. Bussel, M. Arning, M. Aivado, 2011, The Lancet.

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

M. Galsky, N. Vogelzang, M. Saleh, 2014, Clinical Cancer Research.

Advances in monoclonal antibody therapy of cancer.

A. Lobuglio, M. Saleh, M. Saleh, 1992, The American journal of the medical sciences.

Promoting Clinical Breast Evaluations in a Lower Middle–Income Country Setting: An Approach Toward Achieving a Sustainable Breast Health Program

F. Amersi, Saleem Sayani, M. Saleh, 2018, Journal of global oncology.

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

Joshua M. Dempster, Henry W. Long, B. Haas, 2018, Nature Communications.

Effect of commercial immunoglobulin G preparation on human monocyte Fc‐receptor dependent binding of antibody coated platelets

A. Lobuglio, M. Saleh, W. Huster, 1988, British journal of haematology.

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

G. Naik, G. Shapiro, F. Meric-Bernstam, 2021, Clinical Cancer Research.

CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)

A. Forero, A. Lobuglio, M. Saleh, 2013 .

Generation of a human anti-idiotypic antibody that mimics the GD2 antigen.

A. Lobuglio, M. Khazaeli, M. Saleh, 1993, Journal of immunology.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

A. Stopeck, A. Forero, D. Yardley, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Suzanne F. Jones, L. Hart, J. Bendell, 2014, Journal of Clinical Oncology.

Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women

S. Varambally, U. Manne, I. Eltoum, 2021, Translational oncology.

Clinical Investigator Training Program (CITP) – A practical and pragmatic approach to conveying clinical investigator competencies and training to busy clinicians

G. Naik, J. Willig, M. Dransfield, 2020, Contemporary clinical trials communications.

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

Joshua M. Dempster, Henry W. Long, E. D. Jacobsen, 2018, Nature Communications.

Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post‐hoc analysis of the EXTEND study

J. Bussel, A. Khelif, M. Saleh, 2021, British journal of haematology.

Changes in health‐related quality of life with long‐term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study

J. Bussel, M. Duh, A. Khelif, 2018, American journal of hematology.

EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010

J. Bussel, Huiping Sun, M. Saleh, 2010 .

Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura.

J. Bussel, M. Arning, B. Psaila, 2008 .

Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya

J. Figueroa, D. Govender, S. Sayed, 2021, Breast Cancer Research.

Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya

J. Figueroa, D. Govender, S. Sayed, 2021, Breast Cancer Research.

Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study.

J. Bussel, M. Aivado, B. Meddeb, 2009 .

Thromboembolic Events Observed in Eltrombopag Clinical Trials in Chronic Immune Thrombocytopenic Purpura.

J. Bussel, M. Aivado, M. Saleh, 2009 .

Results of Bone Marrow Examinations in Patients with Chronic Immune Thrombocytopenic Purpura Treated with Eltrombopag.

J. Bussel, M. Aivado, M. Saleh, 2009 .

Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura.

J. Bussel, M. Aivado, B. Meddeb, 2008 .

Safety and Efficacy of Extended Treatment with Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2011

J. Bussel, M. Saleh, G. Cheng, 2011 .

Low‐dose anti‐CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study

J. Bussel, D. Goldenberg, W. Wegener, 2013, British journal of haematology.

Eltrombopag for chronic immune thrombocytopenia – Authors' reply

J. Bussel, M. Aivado, M. Saleh, 2011, The Lancet.

The safety profile of eltrombopag, a novel oral platelet growth factor, in thrombocytopenic patients and healthy subjects.

J. M. Hamilton, R. Rafi, M. Saleh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

L. Gordon, M. Czuczman, I. Flinn, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Experience with Murine, Human and Genetically Engineered Monoclonal Antibodies

A. Lobuglio, M. Saleh, R. Conry, 1994 .

Monoclonal antibody therapy of cancer.

A. Lobuglio, M. Saleh, M. Saleh, 1992, Critical reviews in oncology/hematology.

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

L. Hart, J. Infante, R. Beckman, 2013, Cancer medicine.

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

M. Buyse, G. Sauter, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC).

H. Scher, E. Antonarakis, R. Hauke, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intrathecal cytosine arabinoside-induced acute, rapidly reversible paralysis.

M. Saleh, E. S. Christian, B. Diamond, 1989, The American journal of medicine.

A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer

M. Socinski, T. Hensing, T. Stinchcombe, 2009, Cancer investigation.

Pivotal S tudy o f I odine I 1 31 T ositumomab f or Chemotherapy-Ref ractory L ow-Grade o r T ransformed Low-Grade B -Cell N on-Hodgkin's L ymphomas

J. Vose, A. Zelenetz, M. Kaminski, 2001 .

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

A. Italiano, M. Chiron, Chia‐Chi Lin, 2022, Journal for ImmunoTherapy of Cancer.

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

M. Borad, A. Daud, W. Messersmith, 2011, Clinical Cancer Research.

Selection of platelets for refractory patients by HLA matching and prospective crossmatching

J. Rowe, M. Saleh, D. Stroncek, 1992, Transfusion.

Abstract A098: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies

David C. Smith, J. Nemunaitis, T. Ji, 2017 .

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

M. Cobleigh, D. Tripathy, D. Slamon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

R H Wheeler, H W Waksal, S. Spencer, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)

D. Lake, C. Hudis, T. Traina, 2008 .

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.

N. Robert, John W. Davis, K. Kern, 2011, Clinical breast cancer.

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.

C. Flowers, S. de Vos, L. Hart, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer.

C. Jones, K. Bland, A. Forero, 2009 .

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.

K. Gelmon, A. Tolcher, C. Isaacs, 1999, Journal of Clinical Oncology.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

L. Gordon, J. Murray, N. Bartlett, 2002, Blood.

multicenter trial refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or

L. Gordon, J. Murray, T. Witzig, 2013 .

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Suzanne F. Jones, Yulei N. Wang, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.

J. Berlin, A. Daud, K. Lewis, 2017 .

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.

L. Paz-Ares, A. Szczesna, J. Schiller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.

L. Gordon, M. Czuczman, I. Flinn, 2002, Seminars in oncology.

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.

J. Gutheil, J. Butler, A. Lobuglio, 2000, Seminars in oncology.

Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War.

A. Forero-Torres, M. Saleh, 2007, Clinical lymphoma & myeloma.

HUMAN IMMUNE RESPONSE TO CARCINOEMBRYONIC ANTIGEN TUMOR VACCINES

J. Schlom, A. Lobuglio, M. Saleh, 1995 .

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

F. Ravandi, R. Rifkin, M. Saleh, 2004, British journal of haematology.

TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

Brian S. Roberts, R. Myers, Minetta C. Liu, 2020, Breast cancer research : BCR.

Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.

W. Grizzle, W. Grizzle, R. Meredith, 1999, Cancer biotherapy & radiopharmaceuticals.

Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.

J. Nemunaitis, K. Papadopoulos, T. Ji, 2020 .

Association of premature atherosclerotic cardiovascular disease with higher risk of cancer: a behavioral risk factor surveillance system study.

S. Virani, C. Krittanawong, Dhruv Mahtta, 2021, European journal of preventive cardiology.

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

C. Flowers, L. Hart, S. Dakhil, 2005 .

Severe neutropenia and relative dose intensity among patients <65 and ≥65 years with non-Hodgkin’s lymphoma receiving CHOP-based chemotherapy

E. Abella, L. Schwartzberg, M. Saleh, 2014, Supportive Care in Cancer.

Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia.

A. Lobuglio, M. Saleh, D. Shaw, 1987, Blood.

SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.

J. Hecht, S. Dakhil, W. Go, 2015, Clinical colorectal cancer.

Chain Immunotoxin in Non-Hodgkin’s Lymphoma: Effect

E. Vitetta, A. Lobuglio, M. Khazaeli, 2006 .

Promoting Breast Cancer Awareness and Clinical Breast Examination in the LMIC: Experiences from Tajikistan, Pakistan and Kenya

F. Amersi, M. Saleh, Zohray M Talib, 2019, Current Breast Cancer Reports.

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel

C. Higano, L. Fehrenbacher, J. Picus, 2007, Investigational New Drugs.

Tumour Infiltrating Lymphocytes (TILs) and immune composition in breast cancer patients from Kenya: Spatial distributions and associations with risk factors and tumour characteristics

R. Salgado, Patricia D. Castro, D. Govender, 2022, Breast Cancer Research and Treatment.

Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE)

J. Bussel, M. Arning, M. Aivado, 2008 .

Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer

M. Socinski, R. Kurek, Michael Thomas, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract CT124: A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer

H. Lenz, M. Pishvaian, P. O'dwyer, 2018, Clinical Trials.

A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer

H. Lenz, E. Lin, J. Knost, 2014, Cancer medicine.

Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T)

K. Miller, K. Jabboury, A. Hannah, 2007 .

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

A. Tolcher, K. Papadopoulos, B. Schwartz, 2015 .

Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.

G. Shapiro, F. Meric-Bernstam, J. Infante, 2017 .

Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).

Suzanne F. Jones, L. Hart, J. Bendell, 2010 .